← Holdings
VRTX

VERTEX PHARMACEUTICALS INC

3 managers · $252M total
Data: SEC EDGAR 13F · 2026Q2
Manager holders · last 5 qtrs
3
2025Q2 – 2026Q2 · +1 QoQ
Total position
$252M
Combined value across tracked managers
Net move this quarter
↑ Adding
Weighted by holders' share change
HolderQ actionValue% of port.Style
Baillie GiffordAdd+36.68%$135M0.12%Long-term growth / Global allocation
Harris (Oakmark)Add+2.53%$104M0.14%Deep value / Contrarian long-term
MarathonTrim-21.85%$13M0.51%Capital cycle / Contrarian value
What managers say
2026-06-30Baillie Gifford Positive Change FundBullPositive Change Fund Impact Measurement MethodologyDetail →
2024-03-12Colossus (Invest Like the Best / Business Breakdowns)BullAnne-Marie Peterson - The Capital System - [Invest Like the Best, EP.364]Detail →
Earnings Calls

No earnings call data yet

FinancialsFY2025 · Source: SEC EDGAR 10-K

5y revenue CAGR 12% · latest net margin 32.9% · FCF volatile

Revenue$12.0B
Rev. YoY+8.9%
Gross margin86.2%
Net margin32.9%
Net income$3.95B
Free cash flow$3.19B
Operating cash flow$3.63B
ROE21.2%

Source: SEC EDGAR company filings (10-K). Foreign issuers (20-F/IFRS) not yet covered.